T2DM患者随机分为诺和锐组和诺和灵R组,泵治疗1周,结果FPG和睡前血糖下降两组间差异无显著性(P>0.05),PPG诺和和锐组优于诺和灵R组(P<0.05),血糖达标所需时间、胰岛素用量及低血糖发生率低于诺和灵R组(P<0.05)。两组用药前后体重增加无明显差异(P>0.05)。结论泵输注诺和锐和灵R均能使高血糖得到良好控制,但诺和锐更理想。 Patients with T2DM were randomly divided into Nuo-Renrui group and Noropenil-R group, and were treated with pump for 1 week. Results There was no significant difference between FPG and before going to bedtime blood glucose (P> 0.05) (P <0.05). The time required for achieving blood glucose, the amount of insulin and the incidence of hypoglycemia were lower than those of norvirrenol group (P <0.05). There was no significant difference in weight gain between the two groups before and after treatment (P> 0.05). CONCLUSION Pump NovoRui and RY can control hyperglycemia well, but NovoRui is more ideal.